Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugsAppointment initiates ...

Bearish flow noted in Cassava Sciences (SAVA) with 3,180 puts trading, or 1.8x expected. Most active are 11/22 weekly 13 puts and 11/22 weekly 25 puts, with total volume in those strikes near 1,000 ...

For further details on Vaccinex's financials, please refer to its Form 10K filed April 1, 2024, with the SEC, and subsequently filed Quarterly Reports on Form 10-Q. Pepinemab is a humanized IgG4 ...

On Friday, Cassava Sciences Inc (SAVA) stock saw a modest uptick, ending the day at $26.91 which represents a slight increase of $0.77 or 2.95% from the prior close of $26.14. The stock opened at $26.

SEC adopts EDGAR Next - As outlined in this October 22 Cooley alert, the Securities and Exchange Commission (SEC) adopted final ...

STAT+ subscribers can sign up here to get it delivered to their inbox. As we count down toward the December readout of ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.

Please refer to Cassava Sciences' recent filings with the SEC, including Forms 10-K and 10-Q for a description of the factors ...

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

Cassava Sciences has faced a lot of scrutiny, with key figures resigning and the company settling an SEC penalty. Read what ...